Coherus and Junshi Biosciences Announce Toripalimab Studies to be Presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting
27 avr. 2023 08h05 HE
|
Coherus BioSciences, Inc.
SHANGHAI, China and REDWOOD CITY, Calif., April 27, 2023 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences”, HKEX: 1877; SSE: 688180) and Coherus BioSciences, Inc....
Coherus BioSciences Reports Fourth Quarter and Full Year 2022 Results
06 mars 2023 16h01 HE
|
Coherus BioSciences, Inc.
– Net product sales of $45.4 million in the fourth quarter 2022 and $211.0 million in FY 2022 –– FDA is planning the toripalimab manufacturing site inspection in Q2 2023 –– UDENYCA® autoinjector...
FDA Approves UDENYCA® Autoinjector
06 mars 2023 08h00 HE
|
Coherus BioSciences, Inc.
- UDENYCA® is the only pegfilgrastim therapy delivered in a convenient, easy-to-administer prefilled autoinjector to offer in-clinic and at-home administration options for cancer patients undergoing...
Coherus BioSciences to Present at Upcoming Investor Conferences in March
01 mars 2023 08h25 HE
|
Coherus BioSciences, Inc.
REDWOOD CITY, Calif., March 01, 2023 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus“, Nasdaq: CHRS) today announced that senior management will present at the following investor conferences...
Coherus BioSciences to Report Fourth Quarter and Full Year 2022 Financial Results on March 6, 2023
28 févr. 2023 08h25 HE
|
Coherus BioSciences, Inc.
REDWOOD CITY, Calif., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus“, Nasdaq: CHRS) today announced that its fourth quarter and full year 2022 financial results will be...
Coherus and Junshi Biosciences Announce Positive Final Overall Survival Results of JUPITER-02, a Phase 3 Clinical Trial Evaluating Toripalimab as Treatment for Recurrent or Metastatic Nasopharyngeal Carcinoma
15 févr. 2023 08h25 HE
|
Coherus BioSciences, Inc.
SHANGHAI, China and REDWOOD CITY, Calif., Feb. 15, 2023 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences”, HKEX: 1877; SSE: 688180) and Coherus BioSciences, Inc....
Coherus Granted Permanent, Product-Specific Q-Code for CIMERLI® (ranibizumab-eqrn) from the Centers for Medicare and Medicaid Services
13 févr. 2023 08h25 HE
|
Coherus BioSciences, Inc.
- Q-Code assigned to CIMERLI® for Medicare claims processing effective for dates of service on and after April 1, 2023 - - COHERUS Solutions™ patient services hub is available to facilitate...
Coherus BioSciences Announces New Employment Inducement Grants
03 févr. 2023 17h30 HE
|
Coherus BioSciences, Inc.
REDWOOD CITY, Calif., Feb. 03, 2023 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus” or the “Company”, Nasdaq: CHRS), today announced that effective February 1, 2023, the compensation...
Coherus Agrees to Acquire Exclusive U.S. Commercial Rights to Eylea® Biosimilar FYB203 from Klinge Biopharma
09 janv. 2023 08h20 HE
|
Coherus BioSciences, Inc.
REDWOOD CITY, Calif., Jan. 09, 2023 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Coherus or Coherus BioSciences, Nasdaq: CHRS) announced today that it has executed a binding term sheet with Klinge...
Coherus BioSciences Management to Present at the 41st Annual J.P. Morgan Healthcare Conference
04 janv. 2023 07h01 HE
|
Coherus BioSciences, Inc.
REDWOOD CITY, Calif., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), today announced that senior management will present at the upcoming 41st Annual J.P....